Solid Biosciences (SLDB) Receivables (2021)
Quarterly results put Receivables at $220000.0 for Q4 2021, changed N/A from a year ago — trailing twelve months through Dec 2021 was $220000.0 (changed N/A YoY), and the annual figure for FY2021 was $220000.0, changed.
Solid Biosciences has reported Receivables over the past 1 years, most recently at $220000.0 for Q4 2021.
- Receivables reached $220000.0 in Q4 2021 per SLDB's latest filing.
- Across five years, Receivables topped out at $220000.0 in Q4 2021 and bottomed at $220000.0 in Q4 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 13.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 4.97 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 2.00 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 5.73 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 883.96 Mn |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 220,000.00 |